Skip to main
SGRY

Surgery Partners (SGRY) Stock Forecast & Price Target

Surgery Partners (SGRY) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 38%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Surgery Partners is well positioned to continue generating strong growth, with a diverse portfolio of ambulatory surgical centers and short-stay hospitals. The recent divestiture of its Idaho Falls market will have a positive impact on revenue, EBITDA, and balance sheet leverage, allowing the company to focus on its high-efficiency facilities and expand its capabilities in targeted high-acuity specialties. The company's strategic investments, de novo pipeline, and disciplined M&A strategy support a multi-year growth story, leading to sustainable, double-digit EBITDA growth and long-term value creation for shareholders.

Bears say

Surgery Partners is heavily dependent on managed care and Medicare payment rates, which are subject to change and could negatively impact the company's financial performance. There is also a risk of integration challenges as the company continues to acquire new assets. Additionally, labor cost inflation and revenue concentration pose potential threats to the company's profitability. Despite recent divestitures, Surgery Partners remains highly leveraged and may face difficulties in managing its debt load. Overall, these factors make the stock unattractive for investment, with a low likelihood of significant price appreciation.

Surgery Partners (SGRY) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 38% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Surgery Partners and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Surgery Partners (SGRY) Forecast

Analysts have given Surgery Partners (SGRY) a Buy based on their latest research and market trends.

According to 8 analysts, Surgery Partners (SGRY) has a Buy consensus rating as of Sep 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Surgery Partners (SGRY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.